PL1661890T3 - Związek aktywujący PPAR oraz kompozycja farmaceutyczna zawierająca ten związek - Google Patents
Związek aktywujący PPAR oraz kompozycja farmaceutyczna zawierająca ten związekInfo
- Publication number
- PL1661890T3 PL1661890T3 PL04772699T PL04772699T PL1661890T3 PL 1661890 T3 PL1661890 T3 PL 1661890T3 PL 04772699 T PL04772699 T PL 04772699T PL 04772699 T PL04772699 T PL 04772699T PL 1661890 T3 PL1661890 T3 PL 1661890T3
- Authority
- PL
- Poland
- Prior art keywords
- ppar
- pharmaceutical composition
- composition containing
- containing same
- activating compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49935703P | 2003-09-03 | 2003-09-03 | |
| JP2003317353 | 2003-09-09 | ||
| JP2003364817 | 2003-10-24 | ||
| EP04772699A EP1661890B1 (en) | 2003-09-03 | 2004-09-02 | Ppar-activating compound and pharmaceutical composition containing same |
| PCT/JP2004/012750 WO2005023777A1 (ja) | 2003-09-03 | 2004-09-02 | Ppar活性化化合物及びこれを含有する医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1661890T3 true PL1661890T3 (pl) | 2011-06-30 |
Family
ID=34279568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04772699T PL1661890T3 (pl) | 2003-09-03 | 2004-09-02 | Związek aktywujący PPAR oraz kompozycja farmaceutyczna zawierająca ten związek |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7109226B2 (pl) |
| EP (1) | EP1661890B1 (pl) |
| JP (2) | JP4226005B2 (pl) |
| KR (1) | KR101160808B1 (pl) |
| AU (1) | AU2004270538C1 (pl) |
| BR (1) | BRPI0413991B8 (pl) |
| CA (1) | CA2535749C (pl) |
| CY (1) | CY1111867T1 (pl) |
| EA (1) | EA009374B1 (pl) |
| HR (1) | HRP20110009T1 (pl) |
| IL (1) | IL173639A (pl) |
| MX (1) | MXPA06002435A (pl) |
| NO (1) | NO335823B1 (pl) |
| NZ (1) | NZ545692A (pl) |
| PL (1) | PL1661890T3 (pl) |
| TW (1) | TWI324599B (pl) |
| WO (1) | WO2005023777A1 (pl) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1633774B1 (en) * | 2003-06-18 | 2010-02-17 | Tranzyme Pharma Inc. | Macrocyclic antagonists of the motilin receptor |
| SI1648922T1 (sl) * | 2003-07-31 | 2011-03-31 | Tranzyme Pharma Inc | Prostorsko opredeljene makrocikliäśne spojine uporabne za odkrivanje zdravil |
| US7398116B2 (en) | 2003-08-11 | 2008-07-08 | Veran Medical Technologies, Inc. | Methods, apparatuses, and systems useful in conducting image guided interventions |
| US7301033B2 (en) * | 2005-01-27 | 2007-11-27 | Kowa Co., Ltd. | PPAR-activating compound |
| PL1852426T3 (pl) * | 2005-02-23 | 2014-04-30 | Kowa Co | Sposób wytwarzania optycznie czynnego związku aktywującego PPAR oraz związku pośredniego |
| EP1854779A4 (en) * | 2005-03-01 | 2010-07-21 | Kowa Co | OPTICALLY ACTIVE, PPAR-ACTIVATING COMPOSITE INTERMEDIATE PRODUCT AND MANUFACTURING METHOD THEREFOR |
| ES2342319T3 (es) * | 2005-05-31 | 2010-07-05 | Kowa Co., Ltd. | Procedimiento para la produccion de compuestos para activar ppar opticamente activos. |
| WO2007013555A1 (ja) | 2005-07-28 | 2007-02-01 | Kowa Co., Ltd. | 光学活性２－ヒドロキシ酪酸エステルの製造法 |
| US8088733B2 (en) * | 2006-07-06 | 2012-01-03 | Tranzyme Pharma Inc. | Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders |
| WO2008094860A2 (en) * | 2007-01-30 | 2008-08-07 | Allergan, Inc. | Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists |
| TWI407955B (zh) * | 2007-03-29 | 2013-09-11 | Kowa Co | 高脂血症之預防及／或治療劑 |
| JP5679458B2 (ja) | 2009-09-28 | 2015-03-04 | 興和株式会社 | 内臓脂肪重量の低下剤 |
| TWI425948B (zh) * | 2012-01-20 | 2014-02-11 | Compositions for the inhibition or killing of Porphyromonas gingivalis and their use for the alleviation or treatment of periodontal disease and other diseases | |
| PL2902025T3 (pl) * | 2012-09-27 | 2020-03-31 | Kowa Company Ltd. | Środek terapeutyczny przeciwko dyslipidemii |
| WO2014157607A1 (ja) | 2013-03-29 | 2014-10-02 | 興和株式会社 | ２－ヒドロキシカルボン酸又はその誘導体の光学純度向上法 |
| TWI696462B (zh) * | 2013-07-10 | 2020-06-21 | 日商興和股份有限公司 | 非酒精性脂肪性肝疾病治療劑 |
| KR20240152981A (ko) | 2013-08-28 | 2024-10-22 | 교와 가부시키가이샤 | 지질 이상증 치료제 |
| EP3091970B1 (en) * | 2014-01-10 | 2020-10-28 | Rgenix, Inc. | Lxr agonists and uses thereof |
| TWI691331B (zh) * | 2014-09-26 | 2020-04-21 | 日商興和股份有限公司 | 脂質異常症治療劑 |
| TW201618777A (zh) * | 2014-09-26 | 2016-06-01 | 興和股份有限公司 | 脂質異常症治療劑 |
| JP6850730B2 (ja) * | 2015-11-12 | 2021-03-31 | 学校法人 聖マリアンナ医科大学 | 緑内障予防治療剤 |
| ES2847168T5 (es) | 2016-07-29 | 2024-02-20 | Kowa Co | Métodos para prevenir acontecimientos cardiovasculares en poblaciones dislipidémicas de riesgo residual |
| JP2019059673A (ja) * | 2016-08-25 | 2019-04-18 | 興和株式会社 | Ｐｂｃの治療剤 |
| US20210069157A1 (en) * | 2016-08-25 | 2021-03-11 | Kowa Company, Ltd. | Agent for treatment of pbc |
| EP3569250B1 (en) | 2017-01-11 | 2025-04-30 | Kowa Company, Ltd. | Pemafibrate in combination with a sglt2 inhibitor for the prophylactic or therapeutic treatment of liver diseases nonalcoholic fatty liver disease |
| US10314825B2 (en) | 2017-02-24 | 2019-06-11 | Kowa Company, Ltd. | Agent for treatment of PBC |
| WO2019004466A1 (ja) | 2017-06-30 | 2019-01-03 | 興和株式会社 | 医薬 |
| JPWO2019004452A1 (ja) * | 2017-06-30 | 2020-04-30 | 興和株式会社 | 医薬組成物 |
| EP3646864A4 (en) | 2017-06-30 | 2021-03-17 | Kowa Company, Ltd. | PHARMACEUTICAL COMPOSITION CONTAINING PEMAFIBRATE |
| WO2019004447A1 (ja) * | 2017-06-30 | 2019-01-03 | 興和株式会社 | 医薬組成物 |
| CN110809470A (zh) * | 2017-06-30 | 2020-02-18 | 兴和株式会社 | 医药品 |
| WO2019004448A1 (ja) * | 2017-06-30 | 2019-01-03 | 興和株式会社 | 医薬組成物 |
| CN110831591A (zh) * | 2017-06-30 | 2020-02-21 | 兴和株式会社 | 医药组合物 |
| JP6959049B2 (ja) * | 2017-06-30 | 2021-11-02 | 興和株式会社 | 新規低アルブミン血症改善薬 |
| EP3646863B1 (en) * | 2017-06-30 | 2024-01-03 | Kowa Company, Ltd. | Pharmaceutical composition |
| WO2019004451A1 (ja) * | 2017-06-30 | 2019-01-03 | 興和株式会社 | 医薬組成物 |
| AU2018373028A1 (en) | 2017-11-21 | 2020-04-30 | Inspirna, Inc. | Polymorphs and uses thereof |
| US11446282B2 (en) | 2017-12-21 | 2022-09-20 | Kowa Company, Ltd. | Methods of treating mixed dyslipidemia and hypertriglycertdemia |
| WO2019126597A1 (en) * | 2017-12-21 | 2019-06-27 | Kowa Company, Ltd. | Methods of treatment of hypertrigl yceridemia |
| EP3732168A1 (en) * | 2017-12-27 | 2020-11-04 | Teva Pharmaceuticals International GmbH | Solid state forms of pemafibrate |
| JP7356968B2 (ja) | 2018-05-08 | 2023-10-05 | 国立大学法人 岡山大学 | 心血管疾患に有用な医薬 |
| WO2020138406A1 (ja) * | 2018-12-27 | 2020-07-02 | 興和株式会社 | 医薬組成物 |
| JP2020105174A (ja) * | 2018-12-27 | 2020-07-09 | 興和株式会社 | 医薬組成物 |
| EP3903781A4 (en) | 2018-12-27 | 2023-01-25 | Kowa Company, Ltd. | PHARMACEUTICAL PREPARATION |
| US20220000786A1 (en) * | 2018-12-27 | 2022-01-06 | Kowa Company, Ltd. | Pharmaceutical preparation |
| MX2022007164A (es) | 2019-12-13 | 2022-09-12 | Inspirna Inc | Sales metálicas y usos de estas. |
| WO2022224962A1 (ja) | 2021-04-20 | 2022-10-27 | 興和株式会社 | 脂質異常症又は心臓血管病の予防・治療のための組合せ医薬 |
| US20240216342A1 (en) | 2021-04-28 | 2024-07-04 | Kowa Company, Ltd. | Blood carnitine-increasing agent |
| TW202404944A (zh) | 2022-03-31 | 2024-02-01 | 學校法人慈惠大學 | 呼吸器官疾病治療劑 |
| JPWO2024010030A1 (pl) | 2022-07-06 | 2024-01-11 | ||
| TW202408500A (zh) | 2022-07-15 | 2024-03-01 | 日商興和股份有限公司 | 血中ｌｄｌ膽固醇降低劑 |
| WO2024201358A1 (en) * | 2023-03-31 | 2024-10-03 | Ami Lifesciences Private Limited | A process for the preparation of pemafibrate and intermediates thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS593465B2 (ja) * | 1974-06-04 | 1984-01-24 | 藤沢薬品工業株式会社 | チカンアミノアルキルチカンフエノキシカルボンサンルイノ セイゾウホウ |
| JPS6025425B2 (ja) * | 1975-03-06 | 1985-06-18 | 藤沢薬品工業株式会社 | 置換フエノキシ脂肪酸類の合成法 |
| WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| WO2002046176A1 (fr) * | 2000-12-05 | 2002-06-13 | Nippon Chemiphar Co., Ltd. | Activateurs de recepteur active par le proliferateur de peroxisome |
| DE10151390A1 (de) * | 2001-10-18 | 2003-05-08 | Bayer Ag | Essigsäurederivate |
| JP4383177B2 (ja) * | 2002-03-01 | 2009-12-16 | スミスクライン ビーチャム コーポレーション | ｈＰＰＡＲ活性化剤 |
| US6653334B1 (en) * | 2002-12-27 | 2003-11-25 | Kowa Co., Ltd. | Benzoxazole compound and pharmaceutical composition containing the same |
-
2004
- 2004-09-02 HR HR20110009T patent/HRP20110009T1/hr unknown
- 2004-09-02 EA EA200600527A patent/EA009374B1/ru not_active IP Right Cessation
- 2004-09-02 WO PCT/JP2004/012750 patent/WO2005023777A1/ja active Application Filing
- 2004-09-02 NZ NZ545692A patent/NZ545692A/xx not_active IP Right Cessation
- 2004-09-02 KR KR1020067003950A patent/KR101160808B1/ko not_active Expired - Fee Related
- 2004-09-02 EP EP04772699A patent/EP1661890B1/en not_active Expired - Lifetime
- 2004-09-02 PL PL04772699T patent/PL1661890T3/pl unknown
- 2004-09-02 MX MXPA06002435A patent/MXPA06002435A/es active IP Right Grant
- 2004-09-02 BR BRPI0413991A patent/BRPI0413991B8/pt not_active IP Right Cessation
- 2004-09-02 CA CA2535749A patent/CA2535749C/en not_active Expired - Fee Related
- 2004-09-02 JP JP2005513668A patent/JP4226005B2/ja not_active Expired - Lifetime
- 2004-09-02 AU AU2004270538A patent/AU2004270538C1/en not_active Ceased
- 2004-09-03 TW TW093126702A patent/TWI324599B/zh not_active IP Right Cessation
- 2004-09-03 US US10/933,467 patent/US7109226B2/en not_active Expired - Lifetime
-
2006
- 2006-02-09 NO NO20060654A patent/NO335823B1/no not_active IP Right Cessation
- 2006-02-09 IL IL173639A patent/IL173639A/en active IP Right Grant
- 2006-04-20 US US11/407,076 patent/US7183295B2/en not_active Expired - Lifetime
-
2008
- 2008-10-31 JP JP2008281020A patent/JP4931893B2/ja not_active Expired - Fee Related
-
2011
- 2011-03-31 CY CY20111100343T patent/CY1111867T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL173639A (en) | Ppar-activating compound and pharmaceutical composition containing same | |
| IL174128A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
| IL197889A (en) | Pyridylvinylazacyclopentane compound and pharmaceutical compositions comprising same | |
| IL173602A0 (en) | Heteroarylaminosulfonylphenyl derivatives and pharmaceutical compositions containing the same | |
| IL173627A0 (en) | 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives and pharmaceutical compositions containing the same | |
| IL173051A0 (en) | N-glucoside derivatives and pharmaceutical compositions containing the same | |
| IL175214A0 (en) | 2-cyanopyrrolidinecarboxamide derivatives and pharmaceutical compositions containing the same | |
| IL164455A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
| IL171997A0 (en) | Pyrrolodihydroisoquinoline derivatives and pharmaceutical compositions containing the same | |
| IL174249A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
| AU2003291103A8 (en) | Pharmaceutical composition | |
| IL165388A0 (en) | Macrolide compounds and pharmaceutical compositions containing the same | |
| IL164547A0 (en) | Pharmaceutical composition | |
| IL172159A0 (en) | 2-oxo-pyridine derivatives and pharmaceutical compositions containing the same | |
| GB0300427D0 (en) | Pharmaceutical composition | |
| IL165878A0 (en) | Pharmaceutical composition | |
| GB0307866D0 (en) | Pharmaceutical composition | |
| IL176077A0 (en) | 1-n-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them | |
| EP1699458A4 (en) | PHARMACEUTICAL COMPOSITION | |
| GB0317663D0 (en) | Pharmaceutical composition | |
| GB0300885D0 (en) | Pharmaceutical composition | |
| ZA200601232B (en) | 3-Aryl-4-hydroxyfuranone compounds and pharmaceutical and veterinary compositions containing them | |
| GB0306933D0 (en) | Pharmaceutical composition | |
| GB0307869D0 (en) | Pharmaceutical composition | |
| GB0307867D0 (en) | Pharmaceutical composition |